FDA Approved: PRADAXA — Supplemental Application (Boehringer Ingelheim Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved Boehringer Ingelheim Pharmaceuticals' supplemental application for Pradaxa (dabigatran etexilate mesylate).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Nonvalvular Atrial Fibrillation
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• Pradaxa (dabigatran etexilate)

Snippet

SUPPL AP for PRADAXA (DABIGATRAN ETEXILATE MESYLATE)